NPM1 and acute myeloid leukemia: AML patients with recurrent genetic abnormalities such as NPM1 mutation, Core Binding Factor AML or acute promyelocitic leukemia (APL) are the best candidates for such an approach, given the availability of highly sensitive MRD markers; several studies have shown that the administration of pre-DLI improves disease outcomes [31,32].